Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study
2021; RELX Group (Netherlands); Linguagem: Inglês
10.2139/ssrn.3989856
ISSN1556-5068
AutoresSara Y. Tartof, Jeff Slezak, Laura Puzniak, Vennis Hong, Timothy B. Frankland, Bradley K. Ackerson, Harpreet S. Takhar, Oluwaseye Ayoola Ogun, Sarah Simmons, Joann M. Zamparo, Sharon Gray, Srinivas Rao Valluri, Kaijie Pan, Luis Jódar, John M. McLaughlin,
Tópico(s)Vaccine Coverage and Hesitancy
ResumoDownload This Paper Open PDF in Browser Add Paper to My Library Share: Permalink Using these links will ensure access to this page indefinitely Copy URL Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com. Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study 35 Pages Posted: 21 Dec 2021 See all articles by Sara Y. TartofSara Y. TartofKaiser Permanente Southern California - Department of Research & EvaluationJeff M. SlezakKaiser Permanente Southern California - Department of Research & EvaluationLaura PuzniakPfizer, Inc.Vennis HongKaiser Permanente Southern California - Department of Research & EvaluationTimothy B. FranklandKaiser Permanente - Kaiser Permanente Center for Integrated Health Care ResearchBradley K. AckersonKaiser Permanente Southern CaliforniaHarpreet S. TakharKaiser Permanente Southern California - Department of Research & EvaluationOluwaseye A. OgunKaiser Permanente Southern California - Department of Research & EvaluationSarah SimmonsKaiser Permanente Southern California - Department of Research & EvaluationJoann M. ZamparoPfizer, Inc.Sharon GrayPfizer, Inc.Srinivas R. ValluriPfizer, Inc.Kaijie PanPfizer, Inc.Luis JodarPfizer, Inc.John M. McLaughlinPfizer, Inc. More... Abstract Background: Globally, recommendations are expanding for third (booster) doses of BNT162b2. In the United States, as of November 19, 2021, boosters were recommended for all adults aged 18 years and older. We evaluated the effectiveness of a third dose of BNT162b2 among adults in a large US integrated health system.Methods: In this retrospective cohort study, we analyzed electronic health records from Kaiser Permanente Southern California between Dec 14, 2020 and Dec 5, 2021 to assess vaccine effectiveness (VE) of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission. VE was calculated using hazards ratios from adjusted Cox models.Findings: After only two doses, VE against infection declined from 85% (95% CI 83–86) during the first month to 49% (46–51) seven to eight months following vaccination. Overall VE against hospitalization was 90% (95% CI 86–92) within one month and did not wane, however, effectiveness against hospitalization appeared to wane among immunocompromised individuals. Three-dose VE was 88% (95% CI 86–89) against infection and 97% (95–98) against hospitalization. Effectiveness after three doses was higher than that seen one month after receiving only two doses for both outcomes. Relative VE of three doses compared to two (with at least six months after the second dose) was 75% (95% CI 71−78) and 70% (48−83) against infections and hospital admissions, respectively.Interpretation: These data support the benefit of broad BNT162b2 booster recommendations, as three doses confers comparable, if not better, protection against SARS-CoV-2 infections and hospital admission as was seen soon after receiving two doses.Trial Registration: This study was registered with: NCT04848584. Funding: Pfizer Inc.Declaration of Interest: JMZ, SG, SRV, KP, LJ, LP, and JMM are employees of and hold stock and/or stock options in Pfizer Inc. TBF holds stock in Pfizer Inc. SYT, JMS, VH, BA, HT, TF, SRS, and OO received research support from Pfizer during the conduct of this study that was paid directly to KPSC. All other authors report no conflicts.Ethical Approval: The study protocol was reviewed and approved by the KPSC institutional review board which waived requirement for informed consent (number 12816). Keywords: effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta Suggested Citation: Suggested Citation Tartof, Sara Y. and Slezak, Jeff M. and Puzniak, Laura and Hong, Vennis and Frankland, Timothy B. and Ackerson, Bradley K. and Takhar, Harpreet S. and Ogun, Oluwaseye A. and Simmons, Sarah and Zamparo, Joann M. and Gray, Sharon and Valluri, Srinivas R. and Pan, Kaijie and Jodar, Luis and McLaughlin, John M., Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study. Available at SSRN: https://ssrn.com/abstract=3989856 Sara Y. Tartof (Contact Author) Kaiser Permanente Southern California - Department of Research & Evaluation ( email ) Pasadena, CAUnited States Jeff M. Slezak Kaiser Permanente Southern California - Department of Research & Evaluation ( email ) Mission Viejo, CAUnited States Laura Puzniak Pfizer, Inc. La Jolla, CAUnited States Vennis Hong Kaiser Permanente Southern California - Department of Research & Evaluation ( email ) Mission Viejo, CAUnited States Timothy B. Frankland Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research ( email ) Honolulu,, HIUnited States Bradley K. Ackerson Kaiser Permanente Southern California ( email ) Mission Viejo, CAUnited States Harpreet S. Takhar Kaiser Permanente Southern California - Department of Research & Evaluation ( email ) Mission Viejo, CAUnited States Oluwaseye A. Ogun Kaiser Permanente Southern California - Department of Research & Evaluation ( email ) Mission Viejo, CAUnited States Sarah Simmons Kaiser Permanente Southern California - Department of Research & Evaluation ( email ) United States Joann M. Zamparo Pfizer, Inc. ( email ) 235 East 42 StreetNew York, NY 10017United States Sharon Gray Pfizer, Inc. ( email ) 235 East 42 StreetNew York, NY 10017United States Srinivas R. Valluri Pfizer, Inc. ( email ) 235 East 42 StreetNew York, NY 10017United States Kaijie Pan Pfizer, Inc. ( email ) 235 East 42 StreetNew York, NY 10017United States Luis Jodar Pfizer, Inc. La Jolla, CAUnited States John M. McLaughlin Pfizer, Inc. ( email ) 235 East 42 StreetNew York, NY 10017United States Download This Paper Open PDF in Browser Please enable JavaScript to view the comments powered by Disqus. Click here to go to TheLancet.com Go to TheLancet.com Paper statistics Abstract Views 891 Downloads 127 PlumX Metrics Preprints with The Lancet Specialties All Journals (10477) Allergy & Immunology (769) Anaesthesia & Analgesia (34) Cardiology & Vascular Medicine (705) Child & Adoloscence Health (832) Critical Care (393) Dermatology (70) Digital Health (406) Endocrinology (638) Gastroenterology (640) Genetics & Genomics (1768) Geriatrics (119) Global Health (688) Haematology (466) Infectious Diseases (3909) Nephrology (239) Neurology (981) Nutrition (367) Obstetrics & Gynaecology (504) Oncology (2337) Ophthalmology (146) Otolaryngology (83) Planetary Health (110) Primary Care (590) Psychiatry (732) Public Health (2451) Radiology & Medical Imaging (346) Respiratory Medicine (428) Rheumatology & Orthopaedics (338) Surgery (295) Urology (69) Related eJournals Coronavirus & Infectious Disease Research eJournal Follow Coronavirus & Infectious Disease Research eJournal Subscribe to this free journal for more curated articles on this topic FOLLOWERS 817 PAPERS 12,573 Preprints with The Lancet Follow Preprints with The Lancet Subscribe to this free journal for more curated articles on this topic FOLLOWERS 243 PAPERS 10,477 Feedback Feedback to SSRN Feedback (required) Email (required) Submit If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday. SSRN Quick Links SSRN Solutions Research Paper Series Conference Papers Partners in Publishing Jobs & Announcements Newsletter Sign Up SSRN Rankings Top Papers Top Authors Top Organizations About SSRN SSRN Objectives Network Directors Presidential Letter Announcements Contact us FAQs Copyright Terms and Conditions Privacy Policy We use cookies to help provide and enhance our service and tailor content. To learn more, visit Cookie Settings. This page was processed by aws-apollo5 in 0.505 seconds
Referência(s)